Formulary
Glimepiride: Uses, Dosing, Side Effects and Indian Brand Names
Glimepiride is a second-generation sulphonylurea that stimulates insulin secretion by blocking beta-cell KATP channels. It is the most prescribed sulphonylurea in India, used as add-on therapy to metformin in Type 2 diabetes, with hypoglycaemia as its most significant risk.
MedNext Academy | 5 min read
Clinically reviewed by Awaiting clinical review
Glimepiride: Uses, Dosing, Side Effects and Indian Brand Names
Glimepiride is a second-generation sulphonylurea that stimulates insulin secretion by blocking beta-cell KATP channels. It is the most prescribed sulphonylurea in India, used as add-on therapy to metformin in Type 2 diabetes, with hypoglycaemia as its most significant risk.
NEET PG High-Yield: Sulphonylureas act by blocking KATP channels on beta cells (insulin secretagogues). They require functioning beta cells -- useless in Type 1 DM. Hypoglycaemia is the most important side effect (especially in elderly and CKD). Glibenclamide (glyburide) carries the highest hypoglycaemia risk among sulphonylureas. First-generation agent chlorpropamide causes SIADH and disulfiram-like reaction -- classic MCQ differentiators.
Clinical overview
Glimepiride is the most commonly prescribed sulphonylurea in India and is widely used as a second-line oral hypoglycaemic agent (after metformin) for Type 2 diabetes mellitus. It is a second-generation sulphonylurea with several advantages over first-generation agents (chlorpropamide, tolbutamide): once-daily dosing, lower risk of hypoglycaemia, and lesser weight gain compared to glibenclamide (glyburide). Glimepiride has a relatively faster onset and shorter duration than glibenclamide and binds to a different epitope on the SUR1 receptor, allowing faster dissociation and potentially reduced hypoglycaemia risk. However, hypoglycaemia remains the most important adverse effect of all sulphonylureas and is the critical clinical concern, especially in elderly patients, those with renal impairment, and those who skip meals. Sulphonylureas require functioning beta cells to work, which is why they are ineffective in Type 1 diabetes and lose efficacy over time in Type 2 diabetes as beta-cell function declines (secondary failure). In Indian clinical practice, glimepiride is commonly combined with metformin in fixed-dose combination tablets, which is the most frequently prescribed anti-diabetic combination in the country.
Pharmacological class
Glimepiride belongs to the Sulphonylurea (second-generation oral hypoglycaemic agent) class. Glimepiride binds to the sulphonylurea receptor (SUR1) on pancreatic beta-cell KATP channels (Kir6.2/SUR1 complex), causing channel closure, membrane depolarisation, calcium influx through voltage-gated calcium channels, and insulin exocytosis. It is an insulin secretagogue -- it works by stimulating endogenous insulin release from functioning beta cells. Glimepiride also has extrapancreatic effects: it enhances peripheral insulin sensitivity and increases GLUT4 transporter translocation.
Indian brand names and formulations
Available as: Amaryl (Sanofi India), Glimestar (Mankind Pharma), Zoryl (Intas Pharmaceuticals), Glimy (USV Limited).
Tablets: 1 mg, 2 mg, 3 mg, 4 mg. Fixed-dose combinations with metformin: Glimepiride 1 mg + Metformin 500 mg, Glimepiride 2 mg + Metformin 500 mg/1000 mg.
Regulatory status
Glimepiride is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Schedule H prescription drug. Available in fixed-dose combinations with metformin (e.g., Amaryl M, Glycomet GP). Patients must be educated about hypoglycaemia recognition and management.
Indications
- Type 2 diabetes mellitus (second-line after metformin, or first-line if metformin is contraindicated)
- Combination therapy with metformin, pioglitazone, or insulin
- Type 2 diabetes in patients requiring insulin secretion augmentation
Dosing
Start: 1 mg once daily with breakfast. Titrate by 1 mg every 1-2 weeks. Usual maintenance: 1-4 mg once daily. Maximum: 8 mg/day (though >6 mg rarely adds benefit). Take with the first main meal. Renal impairment: start at 1 mg; avoid in severe CKD (eGFR <30 mL/min) due to accumulation of active metabolites. Elderly: start at 1 mg; increased hypoglycaemia risk. NEVER use in Type 1 diabetes.
Contraindications
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Severe hepatic impairment
- Severe renal impairment (eGFR <30 mL/min)
- Known sulphonamide allergy (cross-reactivity is debated but caution advised)
- Pregnancy and breastfeeding
Adverse effects
- Hypoglycaemia (most important and most dangerous -- can be prolonged, especially in elderly and renal impairment)
- Weight gain (insulin is anabolic; typically 1-3 kg)
- GI disturbance (nausea, rarely)
- Skin reactions (rash, pruritus)
- Hyponatraemia (SIADH-like effect -- rare)
- Haematological (rare: agranulocytosis, thrombocytopenia)
- Cholestatic jaundice (very rare)
- Disulfiram-like reaction with alcohol (mainly chlorpropamide; very rare with glimepiride)
Drug interactions
- Drugs potentiating hypoglycaemia: ACE inhibitors, beta-blockers (mask symptoms), fluconazole, clarithromycin, sulphonamide antibiotics
- Drugs reducing hypoglycaemic effect: corticosteroids, thiazide diuretics, phenytoin, rifampicin
- Alcohol -- potentiates hypoglycaemia and rarely causes disulfiram-like flushing
- Warfarin -- sulphonylureas may enhance anticoagulant effect (CYP2C9 competition)
- Miconazole -- potent CYP2C9 inhibitor, markedly increases sulphonylurea levels
Pregnancy and lactation
Category C. Sulphonylureas cross the placenta and can cause neonatal hypoglycaemia and macrosomia by stimulating fetal beta cells. They are contraindicated in pregnancy. Insulin is the drug of choice for diabetes in pregnancy. Metformin is increasingly used in gestational diabetes as an alternative, but sulphonylureas are not first-line.
Exam-style clinical scenario
A 70-year-old diabetic patient on glimepiride 4 mg daily is brought to the emergency department with confusion, sweating, and tremor. Blood glucose is 35 mg/dL. After IV dextrose, his glucose normalises but drops again 4 hours later. Why? Answer: Sulphonylurea-induced hypoglycaemia can be prolonged (lasting 24-72 hours) because glimepiride has a long duration of action (24 hours) and its active metabolites accumulate in elderly patients with declining renal function. Management: (1) Repeated 25% dextrose boluses as needed, (2) 10% dextrose infusion to maintain glucose >100 mg/dL, (3) Admission for at least 24 hours of monitoring, (4) Octreotide (a somatostatin analogue) can be used to suppress endogenous insulin release in refractory cases.
Cost in India
INR 30-70 per strip of 10 tablets (1 mg); INR 40-90 per strip (2 mg); FDC with metformin: INR 50-120
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why is glimepiride preferred over glibenclamide in elderly patients?
Glimepiride has a lower risk of severe hypoglycaemia compared to glibenclamide because: (1) it has a faster dissociation rate from the SUR1 receptor, resulting in less sustained insulin secretion; (2) glibenclamide has an active metabolite (4-trans-hydroxy-glibenclamide) that accumulates in renal impairment and causes prolonged hypoglycaemia; (3) glimepiride has additional extrapancreatic insulin-sensitising effects, meaning less insulin is needed for the same glycaemic effect.
What is secondary failure of sulphonylureas?
Secondary failure refers to the gradual loss of glycaemic efficacy of sulphonylureas over years of treatment (occurring in 5-10% of patients per year). It is primarily due to progressive beta-cell decline (natural history of Type 2 DM) rather than a fault of the drug. Some evidence suggests that chronic sulphonylurea stimulation may accelerate beta-cell exhaustion (beta-cell burnout), though this remains debated. When secondary failure occurs, insulin or other drug classes must be added.
How does octreotide help in sulphonylurea-induced hypoglycaemia?
Octreotide is a somatostatin analogue that inhibits insulin secretion from pancreatic beta cells by activating somatostatin receptors (SSTR2 and SSTR5). In sulphonylurea overdose or refractory hypoglycaemia, octreotide (50 mcg SC every 6-8 hours) suppresses the drug-stimulated insulin release, preventing recurrent hypoglycaemia that is unresponsive to dextrose alone. It is especially useful in deliberate self-harm with sulphonylureas.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Glimepiride
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary